Helius Medical Technologies Inc (HSDT) Quote

HSDT new 52 week low

Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece

IS THIS STOCK A SCAM OR WHAT??? I WANT THE TRUTH!!!

HSDT new 52 week low

HSDT new 52 week low

company received HCPCS codes and CMS reimbursement. They also sign up VA distributor.
Blue Cross is reimbursing

HSDT new 52 lo

HSDT new 52 week

HSDT new 52+ low

Pop

Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) --
-- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually --

NEWTOWN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has partnered with Lovell Government Services (“Lovell”), an SBA-certified Service Disabled Veteran Owned Small Business (“SDVOSB”), to make the Company’s Portable Neuromodulation Stimulator (“PoNS®”) device available to federal healthcare systems. PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from MS when used in conjunction with physical therapy.

“Through their Multiple Sclerosis Centers of Excellence, the VA is dedicated to maximizing the quality of life for veterans suffering from MS, and we are thrilled to partner with Lovell to expand the reach of our innovative PoNS device. In a study of real-world results, after 14 weeks of PoNS Therapy, 100% of MS patients experienced a clinically meaningful improvement in gait. More than 28,000 cases of MS are reported to the VA annually, making PoNS a potential game changer for veterans and their families,” said Dane Andreeff, President and Chief Executive Officer of Helius.

“As the largest integrated healthcare system in the U.S., the VA provides services to veterans with MS from the time of diagnosis through the rest of their lives. Veterans have given their best to our country and should have access to the most innovative and effective resources available. Lovell is proud to introduce this important product to the VA and other federal healthcare providers,” said Chris Lovell, Major, USMC (Ret.), CEO of Lovell Government Services.

“Recently, Helius highlighted the real-life story of Kevin Byrne, a retired U.S. veteran who’s been suffering from MS since 1999. Gait difficulties had taken away his most valued treasure, quality adventures with his 13-year-old daughter, but PoNS Therapy helped him improve his walking by increasing speed, endurance, and distance. After treatment with PoNS, he was able to take his daughter to New York City, where they enjoyed walking the streets and seeing Broadway shows, experiences he thought were lost forever. While clinical results have demonstrated the effectiveness of PoNS Therapy, it’s firsthand accounts like Captain Byrne’s that are the most gratifying,” concluded Andreeff.

https://finviz.com/quote.ashx?t=HSDT&ty=c&ta=1&p=d

https://twitter.com/health_stocks/status/1775480375587811622

$hsdt 7.72

Besides SS...anything promising about this 1?

HSDT: So-called "Medical Research" firms producing NONSENSE gadgets like this should be put in DEATH CAMPS --- along with the 'inventor' of the "NAVAGE" garden hose up one's NOSE!! They are MORONS!! (Fix the UNDERLYING physiological-cellular-GENOMIC problems, you Homo sapiens SHITHEADS!!!)

HSDT: I wouldn't want THAT absurd gadget in my MOUTH, anymore than I'd want a "NAVAGE" in my NOSE, nor up my ASS!!! (What a Medically-IGNORANT Planet we all live on!!!!)

HSDT https://twitter.com/health_stocks/status/1764622834007962029

Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller

Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
-- Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) --

-- Proceeds from recent stock issuances through the Company’s At-The-Market (“ATM”) program extends cash runway into the third quarter 2024 --

NEWTOWN, Pa., March 04, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Centers for Medicare & Medicaid Services (“CMS”) has assigned Healthcare Common Procedure Coding System (“HCPCS”) Level II codes A4593, “Neuromodulation stimulator system, adjunct to rehabilitation therapy regime” to describe the PoNS controller and A4594, “Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece each” to describe the PoNS mouthpiece. The new HCPCS codes will be effective April 1, 2024.

“PoNS Therapy® is life-changing for people who suffer gait impairment due to MS and we’re pleased that CMS understood the benefits of this innovative treatment by establishing HCPCS codes for both the PoNS mouthpiece and controller. This marks a critical reimbursement and access milestone and provides Helius the ability to begin negotiating reimbursement with third-party payers using these unique HCPCS codes. We believe there is a reasonable likelihood that at the public meetings this summer CMS will determine a reimbursement amount for each of the PoNS controller and mouthpiece to take effect on October 1, 2024,” stated Helius’ President and Chief Executive Officer, Dane Andreeff.

“As we pursue widespread reimbursement for PoNS Therapy, we have continued to manage our cash burn. With the recently announced $1.5 million of net proceeds from the sale of shares of our common stock under our ATM program at an average share price of $9.17 per share, our cash runway has been extended into the third quarter of this year. Once we establish reimbursement for PoNS, we believe we will be able to expand reimbursement across third-party payers and have a pathway to positive cash flow as we continue to pursue authorization for stroke in the U.S.,” concluded Andreeff.

PoNS is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from MS and is to be used as an adjunct to a supervised therapeutic exercise program. The Company is also seeking marketing authorization under PoNS’s breakthrough designation for stroke in the United States, where over five million stroke survivors are affected by walking and balance disability. In Canada, PoNS is authorized to treat balance impairment due to MS, stroke and mild-to-moderate traumatic brain injury.

About Helius Medical Technologies, Inc.

The pr pump then the dump

As of November 3, 2023, the registrant had 708,247 shares of Class A common stock, $0.001 par value per share, outstanding.

traded it but made very little money

feels wonky

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
-- Studies uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in stroke patients --

-- Interaction with FDA on clinical program feasibility streamlines cost and timeline and leverages trials with the Medical University of South Carolina and Brooks Rehabilitation --

-- Studies and real-world evidence results will be submitted for regulatory authorization under PoNS’s breakthrough designation for stroke --

-- Regulatory submission for stroke and marketing authorization expected in 2025 --

NEWTOWN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today that it has concluded its interaction with the U.S. Food and Drug Administration (“FDA”) on optimizing the development plan for its stroke program which aims to evaluate the effects of cranial-nerve non-invasive neuromodulation (“CN-NINM”) delivered using PoNS Therapy® on gait and dynamic balance in chronic stroke survivors. Helius’ registrational program includes two controlled studies. The clinical program will leverage a randomized, controlled, double blinded investigator-initiated trial (“IIT”), led by Dr. Steven Kautz at the Medical University of South Carolina (“MUSC”) and a Company-sponsored study to enroll approximately 100 subjects. Dr. Kautz’s IIT began enrollment of 60 participants in September 2023 with the collaboration of Dr. Mark Bowden at Brooks Rehabilitation as a second site.

“Vetting the registrational program and design of our clinical studies with the FDA is an important milestone for Helius and meeting the agency’s expectations will give us the most efficient path to delivering PoNS Therapy to stroke patients,” said Dr. Antonella Favit-Van Pelt, Helius’ Chief Medical Officer. “This development plan, which leverages early study results and real-world evidence from Canada, allows us to streamline the size, timeline, and cost of the registrational program and positions Helius on the best course toward potential FDA authorization under PoNS’s breakthrough designation for stroke.”

When evaluated in a real-world evidence (RWE) database analysis of Canadian stroke patients with gait or balance deficit, PoNS Therapy demonstrated a significant and clinically meaningful improvement in gait, averaging a 6.74-point improvement in the functional gait assessment (FGA) score over a 14-wk treatment period (95% CI: 4.85 to 8.63). Before starting PoNS Therapy, over 93% of patients were considered at risk of falling, as determined by an FGA

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients

Pump it up

I am guessing this is not the platform to talk about HSDT stock seeing as no one has been here for a while.

Interesting. Hopefully they announce FDA approval and/or Medicaid coverage on PONS, or some kind news catalyst. There’s got to be a reason the CEO has been loading. Plus, this past Monday there was a major shift in dollar volume. 200 million dollars traded that day, then every day after that at least a couple million traded. HSDT has never even been close to volume like that. I got a feeling something is brewing.

They don't have much in the books, they are going to do it soon, they only had 8.5 million as of the end of June and each quarter goes by 3.5 million dollars negative in the books and 250,000 dollars in sales, that is nothing, yes true that they don't have any debt, but what else do they have to show for other that 250,000 dollars in sales, that is not enough to cover expenses. 15-20 is the target to get out, anything more than that you are asking for trouble.

All it’s saying is they have the right to add more shares to the total shares outstanding if they choose. They shouldn’t have to do that since they have cash and zero debt, but even if they do one would think they would do it at a much higher PPS then here…

They have not been in effect yet.

https://www.sec.gov/Archives/edgar/data/1610853/000110465923064633/tm2315565-1_s3a.htm

https://www.sec.gov/Archives/edgar/data/1610853/000110465923074253/tm2319321-1_424b5.htm

Can you post a link to this?

Nice runner small float now

I jumped in yesterday on this, Tuesday could hit 15-20, At the Market prospectus has been filed a little while ago for close to 2 million dollars. I won't ask for anything more than 20. Good luck everyone.

$20+ tomorrow IMO

Bye bye float. The fact I got filled on the bid today. All about timing

TGIF - enjoy your long weekend all

Has a few gaps to fill on the way up!!

Fun isn’t it

Boom!

$HSDT RS https://finance.yahoo.com/news/helius-medical-technologies-announces-reverse-130000309.html

https://twitter.com/health_stocks/status/1691797717029151114

Sold

IS IT FINALLY TIME?

Premarket volume on news. PPS up a bit?

HSDT

This one is looking good

Had to grab a few

OMG… Maine !
Sounds like a hidden gem Brother.
Never been that far north. I’m in the Philly / South Jersey area and our winters are no picnic but the area you mentioned is a whole other league LOLOL!!! The winters have to be brutal, but, if push comes to shove … that sounds like a great spot to bug out !!!!
Good night… talk soon.

mis

OMG brother you are so right on with that statement. I know a great location in NW Maine called Moosehead lake. just a few peps live there and it's so secluded that nobody knows how to get there. All the roads are dirt. I went there with my EX Wife years ago and stayed in a cabin on the lake. Many bears and Moose live there so you need their permission to stay. I can't imagine what the winters are like there. I don't even know if they have cell or internet service. lol

Very cool, I will respond back to your PM early Saturday. Email and phone #

Yes Sir my family and I are ok .
These certainly are worrisome times my friend.
A generator, some long term survival food and a shotgun or two are highly recommended.

Hopefully you and yours are ok and prepared as well.
God Bless !

mis

Thanks soo much my friend.
I will send you a d m on Friday happy hour ihub service.
Very much appreciate ya !!!!

Hello, my friend missile_systems! I would not chase this because it's very volitle. If she drops back to where she had been trading then maybe. I have several others I like so send me an email.
Hope you and yours are doing well in this day and age of uncertainty

Hello, my friend missile_systems! I would not chase this because it's very volitle. If she drops back to where she had been trading then maybe. I have several others I like so send me an email.
Hope you and yours are doing well in this day and age of uncertainty